Companies Dominating the Blastomycosis Treatment Landscape
- Emcure Pharmaceuticals Limited
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Viatris Inc.
- Hindustan Antibiotics Limited
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- Sanofi-aventis Groupe
- Abbott Laboratories
- Merck & Co., Inc.
- Siemens Healthcare GmbH
- Pfizer Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of blastomycosis treatment is evaluated at USD 224.75 million.
The blastomycosis treatment market size was over USD 202.46 million in 2024 and is poised to exceed USD 470.41 million by 2037, witnessing over 6.7% CAGR during the forecast period i.e., between 2025-2037. Growing population of immunocompromised patients and the rising geriatric population will boost the market growth.
Asia Pacific industry is predicted to dominate majority revenue share of 40% by 2037, attributed to rising malnutrition and unsanitary conditions in the region.
The major players in the market are Emcure Pharmaceuticals Limited, Viatris Inc., Hindustan Antibiotics Limited, Sun Pharmaceutical Industries Ltd., Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc.
